GSK snags $15 million from Theravance after European approval of asthma, COPD drug

Theravance Inc. will pay GlaxoSmithKline $15 million for winning European approval of the lung disease treatment Relvar Ellipta and will pay out another $15 million when GSK launches the drug commercially...